(1 S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio- d -glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment

Journal of Medicinal Chemistry

Volumn 53, Issue 8, 2010, Pages 3247-3261

  Kakinuma, Hiroyuki ^a   Oi, Takahiro ^a   Hashimoto Tsuchiya, Yuko ^a   Arai, Masayuki ^a   Kawakita, Yasunori ^a   Fukasawa, Yoshiki ^a   Iida, Izumi ^a   Hagima, Naoko ^a   Takeuchi, Hiroyuki ^a   Chino, Yukihiro ^a   Asami, Jun ^a   Okumura Kitajima, Lisa ^a   Io, Fusayo ^a   Yamamoto, Daisuke ^a   Miyata, Noriyuki ^a   Takahashi, Teisuke ^a   Uchida, Saeko ^a   Yamamoto, Koji ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDRO 1 [5 (4 ETHOXYBENZYL) 2 METHOXY 4 METHYLPHENYL] 1 THIO DEXTRO GLUCITOL; ANTIDIABETIC AGENT; AROMATIC COMPOUND; GLUCOSE; PLASMA PROTEIN; PROPRANOLOL; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; TS 071; UNCLASSIFIED DRUG; VERAPAMIL; 1,5 ANHYDRO 1 (5 (4 ETHOXYBENZYL) 2 METHOXY 4 METHYLPHENYL) 1 THIOGLUCITOL; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; DRUG DERIVATIVE; SLC5A2 PROTEIN, HUMAN; SORBITOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER CLEARANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORMAL HUMAN; RAT; STRUCTURE ACTIVITY RELATION; URINARY EXCRETION; ANIMAL; BIOAVAILABILITY; CHO CELL; CRICETULUS; DRUG ANTAGONISM; HAMSTER; LIVER CELL; LIVER MICROSOME; METABOLISM; PROTEIN BINDING; SYNTHESIS; TISSUE DISTRIBUTION; ZUCKER RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CHO CELLS; CRICETINAE; CRICETULUS; DIABETES MELLITUS, TYPE 2; DOGS; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; MICROSOMES, LIVER; PROTEIN BINDING; RATS; RATS, ZUCKER; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 77951143723     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901893x     Document Type: Article

References (53)

1. King, H.; Aubert, R. E.; Herman, W. H. Global Burden of Diabetes, 1995-2025: Prevalence, Numerical Estimates, and Projections Diabetes Care 1998, 21, 1414-1431
2. Golden, S. H.; Robinson, K. A.; Saldanha, I.; Anton, B.; Ladenson, P. W. Prevalence and Incidence of Endocrine and Metabolic Disorders in the United States: a Comprehensive Review J. Clin. Endocrinol. Metab. 2009, 94, 1853-1878
3. International Diabetes Federation. Diabetes Atlas, 3 rd ed.; International Diabetes Federation: Brussels, Belgium, 2006.
4. Morrish, N. J.; Wang, S. L.; Stevens, L. K.; Fuller, J. H.; Keen, H. Mortality and Causes of Death in the WHO Multinational Study of Vascular Disease in Diabetes Diabetologia 2001, 44, S14-S21
5. Leclercq-Meyer, V.; Akkan, A. G.; Marchand, J.; Malaisse, W. J. Effects of Glimepiride and Glibenclamide on Insulin and Glucagon Secretion by the Perfused Rat Pancreas Biochem. Pharmacol. 1991, 42, 1634-1637
6. Davidson, M. B.; Peters, A. L. An Overview of Metformin in the Treatment of Type 2 Diabetes Mellitus Am. J. Med. 1997, 102, 99-110
7. Horii, S.; Fukase, H.; Matsuo, T.; Kameda, Y.; Asano, N.; Matsui, K. Synthesis and α- D -Glucosidase Inhibitory Activity of N -Substituted Valiolamine Derivatives as Potential Oral Antidiabetic Agents J. Med. Chem. 1986, 29, 1038-1046
8. Momose, Y.; Meguro, K.; Ikeda, H.; Hatanaka, C.; Oi, S.; Shoda, T. Studies on Antidiabetic Agents. X. Synthesis and Biological Activities of Pioglitazone and Related Compounds Chem. Pharm. Bull. 1991, 39, 1440-1445
9. Bedu, E.; Wahli, W.; Desvergne, B. Peroxisome Proliferator-Activated Receptor β/Δ as a Therapeutic Target for Metabolic Diseases Expert Opin. Ther. Targets 2005, 9, 861-873
10. Drucker, D. J. Therapeutic Potential of Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes Expert Opin. Investig. Drugs 2003, 12, 87-100
11. Mu, J.; Woods, J.; Zhou, Y.-P.; Roy, R. S.; Li, Z.; Zycband, E.; Feng, Y.; Zhu, L.; Li, C.; Howard, A. D.; Moller, D. E.; Thornberry, N. A.; Zhang, B. B. Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes Diabetes 2006, 55, 1695-1704
12. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Roy, R. S.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. (2 R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α] pyrazin-7(8 H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes J. Med. Chem. 2005, 48, 141-151
13. +-Glucose Cotransporters Am. J. Physiol. Renal. Physiol. 2001, 280, F10-F18
14. Moe, O. W.; Berry, C. A.; Rector, F. C. Renal Transporter of Glucose, Amino Acid, Sodium, Chloride and Water. In The Kidney, 5 th ed.; Brenner, B. M.; Rector, F. C., Eds.; WB Saunders Co.: Philadelphia, 2000; pp 374 - 415.
15. +/Glucose Cotransporter Gene SGLT2 to Human Chromosome 16 Close to the Centromere Genomics 1993, 17, 787-789
16. +-coupled Glucose Transporters in Adult and Embryonic Rat Kidney J. Biol. Chem. 1995, 270, 29365-29371
17. Hediger, M. A.; Rhoads, D. B. Molecular Physiology of Sodium-Glucose Cotransporters Physiol. Rev. 1994, 74, 993-1026
18. Mckee, F. W.; Hawkins, W. B. Phlorizin Glucosuria Physiol. Rev. 1945, 25, 255-280
19. +, D -Glucose Cotransporter a Model Biochim. Biophys. Acta 1982, 688, 557-571
20. +- Glucose Cotransporter Inhibitor T-1095 Br. J. Pharmacol. 2001, 132, 578-586
21. +-Glucose Cotransporters in Streptozotocin-Induced Diabetic Rats Biol. Pharm. Bull. 2000, 23, 1434-1437
22. +-Glucose Cotransporter (SGLT) Inhibitors as Antidiabetic Agents. 4. Synthesis and Pharmacological Properties of 4′-Dehydroxyphlorizin Derivatives Substituted on the B Ring J. Med. Chem. 1999, 42, 5311-5324
23. +-Glucose Cotransporter, in Neonatally Streptozotocin-Treated Rats Eur. J. Pharmacol. 2000, 391, 183-192
24. Handlon, A. L. Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors as Potential Antidiabetic Agents Expert Opin. Ther. Patents 2005, 15, 1531-1540
25. Katsuno, K.; Fujimori, Y.; Takemura, Y.; Hiratochi, M.; Itoh, F.; Komatsu, Y.; Fujikura, H.; Isaji, M. Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level J. Pharmacol. Exp. Ther. 2007, 320, 323-330
26. Fujimori, Y.; Katsuno, K.; Nakashima, I.; Ishikawa-Takemura, Y.; Fujikura, H.; Isaji, M. Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models J. Pharmacol. Exp. Ther. 2008, 327, 268-276
27. +-Glucose cotransporter (SGLT) inhibitors Bioorg. Med. Chem. Lett. 2003, 13, 2269-2272
28. Ellsworth, B.; Washburn, W. N.; Sher, P. M.; Wu, G.; Meng, W.; C -Aryl Glucoside SGLT2 Inhibitors. PCT Int Appl. WO2001027128, 2001; Chem. Abstr. 2001, 134, 281069.
29. Toyama, Y.; Kobayashi, Y.; Noda, A.; Toyama, I.; Toyama, T. C -Glycosides and Preparation of Thereof as Antidiabetic Agents. US Patent 6627611, 2001; Chem. Abstr. 2001, 135, 304104.
30. Washburn, W. N. Evolution of Sodium Glucose Co-Transporter 2 Inhibitors as Anti-Diabetic Agents Expert Opin. Ther. Patents 2009, 19, 1485-1499
31. Meng, W.; Ellsworth, B. A.; Nirschl, A. A.; McCann, P. J.; Patel, M.; Girotra, R. N.; Wu, G.; Sher, P. M.; Morrison, E. P.; Biller, S. A.; Zahler, R.; Deshpande, P. P.; Pullockaran, A.; Hagan, D. L.; Morgan, N.; Taylor, J. R.; Obermeier, M. T.; Humphreys, W. G.; Khanna, A.; Discenza, L.; Robertson, J. G.; Wang, A.; Han, S.; Wetterau, J. R.; Janovitz, E. B.; Flint, O. P.; Whaley, J. M.; Washburn, W. N. Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes J. Med. Chem. 2008, 51, 1145-1149
32. Washburn, W. N. Development of the Renal Glucose Reabsorption Inhibitors: A New Mechanism for the Pharmacotherapy of Diabetes Mellitus Type 2 J. Med. Chem. 2009, 52, 1785-1794
33. Imamura, M.; Murakami, T.; Shiraki, R.; Ikegai, K.; Sugane, T.; Iwasaki, F.; Kurosaki, E.; Tomiyama, H.; Noda, A.; Kitta, K.; Kobayashi, Y. C -Glycoside Derivatives and Salts Thereof. PCT Int Appl. WO2004080990, 2004; Chem. Abstr. 2004, 141, 296242.
34. Nomura, S.; Kawanishi, E.; Ueta, K. Novel Compounds Having Inhibitory Activity Against Sodium-Dependent Transporter. PCT Int Appl. WO2005012326, 2005; Chem. Abstr. 2005, 143, 387313.
35. Eckhardt, M.; Eickelmann, P.; Himmelsbach, F.; Barsoumian, E. L.; Thomas, L. Glucopyranosyl-Substituted Phenyl Derivatives, Drugs Containing Said Compounds, The Use Thereof and Method for the Production Thereof. PCT Int Appl. WO20050092877, 2005; Chem. Abstr. 2005, 143, 286629.
36. Kobayashi, T.; Sato, T.; Nishimoto, M. Spiroketal Derivative and Use Thereof as Diabetic Medicine. PCT Int Appl. WO2006080421, 2006; Chem. Abstr. 2006, 145, 189115.
37. Goodwin, N. C.; Harrison, B. A.; Kimball, S. D.; Mabon, R.; Rawlins, D. B. Inhibitors of Sodium Glucose Co-Transporter 2 Inhibitors. US Patent 20080221164, 2008; Chem. Abstr. 2008, 149, 356147.
38. Goodwin, N. C.; Mabon, R.; Harrison, B. A.; Shadoan, M. K.; Almstead, Z. Y.; Xie., Y.; Healy, J.; Buhring, L. M.; DaCosta, C. M.; Bardenhagen, J.; Mseeh, F.; Liu, Q.; Nouraldeen, A.; Wilson, A. G. E.; Kimball, S. D.; Powell, D. R.; Rawlins, D. B. Novel L-Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes J. Med. Chem. 2009, 52, 6201-6204
39. Yuasa, H.; Hindsgaul, O.; Palcic, M. M. Chemical-Enzymatic Synthesis of 5′-Thio- N -Acetyllactosamine: The First Disaccharide with Sulfur in the Ring of the Nonreducing Sugar J. Am. Chem. Soc. 1992, 114, 5891-5892
40. Hashimoto, H.; Kawanishi, M.; Yuasa, H. Synthesis of Methyl 5′-Thio-α-Isomaltoside via an Acyclic Monothioacetal and its Behavior Toward Glucoamylase Chem. Eur. J. 1996, 2, 556-560
41. Sato, M.; Kakinuma, H.; Asanuma, H. Preparation of Aryl 5-Thio-β- d -Glucopyranoside Derivatives As Remedies for Diabetes. PCT Int Appl. WO2004014931, 2004; Chem. Abstr. 2004, 140, 199631.
42. Kumeda, S.; Asami, J.; Tomoike, H.; Fukuhara, N.; Hachiuma, K.; Sato, M.; Kakinuma, H.; Yamamoto, K.; Miyata, N.; Takahashi, K.; Nakaike, S. SGL0010 is a Novel Orally Active Inhibitor of Sodium-dependent Glucose Cotransporter and Enhances Urinary Glucose Excretion. Presented at the 65th Scientific Sessions of American Diabetes Association, San Diego, CA, June 10-14, 2005, Poster 475-P.
43. Bozó, I.; Boros, S.; Kuszmann, J. Synthesis of 4-Cyanophenyl 1,5-Dithio-β- D -Glucopyranoside and its 6-Deoxy, as well as 6-Deoxy-5-Ene Derivatives as Oral Antithrombotic Agents Carbohydr. Res. 1997, 304, 271-280
44. Postema, M. H. D. C -Glycoside Synthesis; CRC Press: USA, 1995; pp 57 - 60.
45. Yuasa, H.; Tamura, J.; Hashimoto, H. Synthesis of Per- O -alkylated 5-Thio- D -Glucono-1,5-Lactones and Transannular Participation of the Ring Sulphur Atom of 5-Thio- D -glucose Derivatives on Solvolysis under Acidic Conditions J. Chem. Soc. Perkin Trans. 1 1990, 2763-2769
46. H. Driguez, H.; Henrissat, B. A novel synthesis of 5-thio- D -glucose Tetrahedron Lett. 1981, 22, 5061-5062
47. Mehta, S.; Pinto, B. M. Unprecedented Chemical Glycosidation of 5-Thioglucose to Give Disaccharides Tetrahedron Lett. 1992, 33, 7675-7678
48. Kakinuma, H.; Sato, M.; Asanuma, H.; Tomisawa, K. Process for Producing Aldohexopyranose Intermediate. PCT Int Appl. WO2004106352, 2004; Chem. Abstr. 2004, 142, 38476.
49. 3, respectively.
50. Kajimoto, T.; Liu, K. K.-C.; Pederson, R. L.; Zhong, Z.; Ichikawa, Y.; Porco, J. A., Jr.; Wong, C.-H. Enzyme-Catalyzed Aldol Condensation for Asymmetric Synthesis of Azasugars: Synthesis, Evaluation, and Modeling of Glycosidase Inhibitors J. Am. Chem. Soc. 1991, 113, 6187-6196
51. McAllister, R. G., Jr.; Kristen, E. B. The Pharmacology of Verapamil. IV. Kinetic and Dynamic Effects after Single Intravenous and Oral Doses Clin. Pharmacol. Ther. 1982, 31, 418-426
52. Irvine, J. D.; Takahashi, L.; Lockhart, K.; Cheong, J.; Tolan, J. W.; Selick, H. E.; Grove, J. R. MDCK (Madin-Darby canine kidney) cells: A Tool for Membrane Permeability Screening J. Pharm. Sci. 1999, 88, 28-33
53. Obermeier, M.; Yao, M.; Khanna, A.; Koplowitz, B.; Zhu, M.; Li, W.; Komoroski, B.; Kasichayanula, S.; Discenza, L.; Washburn, W.; Meng, W.; Ellsworth, B. A.; Whaley, J. M.; Humphreys, W. G. In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II (SGLT2) Inhibitor, in Animals and Humans. Drug Metab. Dispos. dmd 109.029165, published ahead of print December 8, 2009, doi: 10.1124/dmd.109.029165.